Methods of treating solid tumors with CCR2 antagonists
AssigneesChemoCentryx, Inc., The Regents of the University of California
InventorsJames J. Campbell, Rajinder Singh, Samuel Hwang, Xuesong Wu
Life of this patent
Estimating the term…
Abstract
The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, the method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, the method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula I:
Claims18
A method of treating cutaneous T cell lymphoma (CTCL), said method comprising administering to a subject in need thereof an effective amount of a Chemokine Receptor 2 (CCR2) antagonist, wherein said CCR2 antagonist is a pharmaceutically acceptable salt of a compound selected from the group consisting of
A method of treating cutaneous T cell lymphoma (CTCL), said method comprising administering to a subject in need thereof an effective amount of a Chemokine Receptor 2 (CCR2) antagonist, wherein said CCR2 antagonist is a compound selected from the group consisting of
Dependencies are inferred from the claim text.